Yondelis trabectedin: Interim Phase II data

Interim data from the open-label, Italian Phase II ATREUS trial showed that 7 of 17 evaluable patients with biphasic/sarcomatoid MPM who received 1.3 mg/m 2 IV Yondelis every 3 weeks were alive and free of progression at 12 weeks. ATREUS is enrolling about 79 patients with pretreated epithelioid or biphasic/sarcomatoid MPM. The trial was sponsored by the Mario Negri Institute for Pharmacological Research. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...